Drugs / Salsalate
Salsalate
also known as
Salicylate · 2-hydroxy-benzoic acid, 2-carboxyphenyl ester · DISALCID · Disalicyclic acid · disalicylate · NSC-49171 · Salicylic acid, bimolecular ester · Salicylsalicylic acid · +2 more
Small molecule targets IKBKB via inhibition
Trials 29 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06489249 | Aug 2024 → Jun 2026 overdue | — | University of Iowa | Recruiting | No outcome recorded |
| Phase 0 | NCT05069740 | Jan 2022 → Dec 2025 overdue | endometriosis | Penn State University | Recruiting | No outcome recorded |
| Phase 0 | NCT03482440 | Aug 2018 → Jul 2019 | preeclampsia | University of Iowa | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT03816488 | Dec 2023 → Jun 2024 | hyperglycemia, type 2 diabetes mellitus | McMaster University | Withdrawn | No outcome recorded |
| Phase 1 | NCT03277573 | Jul 2017 → Feb 2022 | Alzheimer disease | Adam Boxer | Completed | No outcome recorded |
| Phase 1 | NCT02422485 | Apr 2015 → Dec 2019 | progressive supranuclear palsy | Adam Boxer | Completed | No outcome recorded |
| Phase 1 | NCT01489319 | Feb 2012 → Jun 2015 | polycystic ovary syndrome | Indiana University | Terminated | No outcome recorded |
| Phase 1 | NCT02130804 | Jul 2011 → Oct 2013 | — | University of Southern California | Completed | No outcome recorded |
| Phase 1 | NCT00837590 | Mar 2009 → Jun 2010 | obesity disorder, prediabetes syndrome | Indiana University | Terminated | No outcome recorded |
| Phase 1 | NCT00553995 | May 2008 → Dec 2013 | — | Boston University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05169060 | Jun 2023 → Feb 2027 expected | diabetic neuropathy | University of Iowa | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT00258128 | Jan 2000 → May 2008 | — | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT04146038 | Oct 2020 → Oct 2021 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT03229408 | Dec 2018 → Feb 2024 | polycystic ovary syndrome | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 2 | NCT03447925 | Jun 2017 → Mar 2019 | palmoplantar keratosis | Universidade do Vale do Sapucai | Completed | No outcome recorded |
| Phase 2 | NCT01977417 | Nov 2012 → Apr 2021 | obesity disorder, prediabetes syndrome | Gary L. Pierce | Terminated | No outcome recorded |
| Phase 2 | NCT01775865 | Sep 2012 → Feb 2016 | arterial disorder, diastolic heart failure | Gary L. Pierce | Completed | No outcome recorded |
| Phase 2 | NCT01506726 | Mar 2012 → Oct 2014 | anemia | Harvey Jay Cohen | Terminated | No outcome recorded |
| Phase 2 | NCT01480297 | Nov 2011 → Apr 2012 | peripheral neuropathy, type 1 diabetes mellitus | University of Michigan | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02936843 | Oct 2016 → May 2023 | peripheral neuropathy, type 1 diabetes mellitus | University of Michigan | Completed | No outcome recorded |
| Phase 2/3 | NCT00624923 | Sep 2008 → Jan 2015 | coronary artery disorder, obesity disorder | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT03222206 | Nov 2017 → Feb 2019 | NAFLD1, osteoarthritis | Korea University Guro Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01712295 | Nov 2011 → Dec 2013 | plantar wart | Grossman, Michael, D.P.M. | Unknown | No outcome recorded |
| Phase 4 | NCT01578486 | Jun 2011 → Jul 2015 | schizoaffective disorder, schizophrenia | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 4 | NCT00339833 | Mar 2003 → Jul 2008 | type 2 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT01514682 | Jun 2012 → Apr 2017 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT01182727 | Aug 2010 → Nov 2011 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT01201759 | Jul 2009 → May 2012 | spinal cord injury | University of Miami | Completed | No outcome recorded |
| — | NCT02406586 | Jul 2009 → Mar 2011 | diabetes mellitus, hypertensive disorder | Emory University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01670773 Comparator | Aug → Oct 2012 | — | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01046682 Comparator | Jan → Jul 2009 | HIV infectious disease | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00258115 Comparator | Dec 2003 → Oct 2007 | obesity disorder | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT00799643 Comparator | Nov 2008 → Sep 2012 | type 2 diabetes mellitus | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00330733 Comparator | Jan 2007 → Aug 2010 | atherosclerosis, diabetes mellitus, noninsulin-dependent, 2 | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2/3 | NCT00392678 Comparator | Oct 2006 → Jul 2008 | type 2 diabetes mellitus | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00760019 Comparator | Aug 2005 → Oct 2009 | atherosclerosis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02007577 Comparator | Jul 2010 → Nov 2013 | prediabetes syndrome | Stanford University | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 40 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salsalate | “1. Salsalate, 4 gm/day. Salsalate is a potent inhibitor of nuclear transcription factor NF-κB activation.” NCT01514682 ↗34 |
| Known as | 2-hydroxy-benzoic acid, 2-carboxyphenyl ester | “The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester.” NCT02422485 ↗ |
| Known as | DISALCID | “Salsalate 750 MG Oral Tablet [DISALCID]” NCT06489249 ↗ |
| Known as | Disalicyclic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | disalicylate | “high-dose salsalate (disalicylate) therapy” PMID 24390146 ↗ Jan 2014 |
| Known as | NSC-49171 | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | Salicylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01712295 ↗ |
| Known as | Salicylic acid, bimolecular ester | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | Salicylsalicylic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | Salsalato | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Known as | Sasapyrine | ChEMBL registry synonym — accepted as the source's own label CHEMBL154111 ↗ |
| Action | Inhibit | “inhibiting the IKKB/NF-kB pathway with salsalate is a feasible approach” NCT00330733 ↗ |
| Modality | Small molecule | “salsalate, a salicylate that reduces basal and inflammation-induced lipolysis” PMID 39888728 ↗ Mar 2025 |
| Route | Oral | “Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided” NCT00392678 ↗ |
| Target | IKBKB | “inhibition of the inhibitor of the κB kinase (IKKβ)/NF-κB pathway” NCT02936843 ↗ |